India’s pharma sector has downplayed the impact of US President Trump’s 25% tariff, warning instead of severe consequences for American healthcare. Industry leaders stressed India’s key role in supplying affordable medicines to the US and predicted shortages, higher costs, and a 3–5 year struggle for the US to find alternatives.
The Headlines – Latest Business News Today: Stock Markets, Financial News, India Business & World Business News – Read More


